AI-Powered Peptide Discovery Offers Breakthrough Treatment Strategy for Ulcerative Colitis and Microbiota Restoration

New machine learning research discovers the LR peptide, a breakthrough treatment for ulcerative colitis that repairs the gut barrier and boosts healthy bacteria.

By: AXL Media

Published: Mar 23, 2026, 11:17 AM EDT

Source: Information for this report was sourced from First Hospital of Jilin University

Accelerating Therapeutic Discovery Through Computational Screening

Ulcerative colitis (UC) remains a persistent challenge for modern medicine, characterized by recurrent abdominal pain and chronic intestinal inflammation that often resists traditional treatments like 5-aminosalicylic acid. To address the need for safer, more targeted therapies, researchers have turned to antimicrobial peptides (AMPs), which are naturally occurring components of the innate immune system. Traditionally, the discovery of these peptides required years of labor-intensive laboratory screening, but the application of a machine learning-based computational approach has allowed scientists to bypass these bottlenecks, rapidly identifying candidates with high therapeutic potential.

Machine Learning Refines Thousands of Potential Sequences

The research team developed a sophisticated pipeline combining peptide prediction models with genetic algorithms to evaluate structural and physicochemical properties. Out of more than 6,000 potential peptide sequences, the model narrowed the search to 22 promising candidates. Through rigorous in vitro testing, a specific peptide named LR was identified for its exceptional balance of high bactericidal activity against pathogens like E. coli and its remarkably low cytotoxicity. This AI-driven selection process ensured that the lead candidate was not only effective at neutralizing harmful bacteria but also safe for human cells and red blood cells.

Superior Efficacy in Resolving Intestinal Damage

In experimental models of induced colitis, the LR peptide demonstrated therapeutic effects that surpassed current clinical standards, including the antibiotic ciprofloxacin. Mice treated with the peptide showed significant improvements in body weight retention and a reduction in colon shortening, which are key clinical indicators of disease severity. Histological examinations further confirmed that LR treatment led to a substantial decrease in mucosal damage and a reduction in the infiltration of inflammatory cells. These results suggest that the peptide could provide a more robust defense against the physical degradation of the colonic lining than existing chemical therapies.